About: http://dx.doi.org/10.1093/cid/ciaa237

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://dx.doi.org/10.1093/cid/ciaa237 Goto Sponge NotDistinct Permalink

An Entity of Type : fabio:Work, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	journal article work
identifier	10020b18a770b4f93c8413bbf60029225d151471
http://purl.org/spar/cito/cites	http://dx.doi.org/10.1016/j.bbrc.2004.08.085 http://dx.doi.org/10.1016/j.ebiom.2017.09.034 http://dx.doi.org/10.1038/s41422-020-0282-0 http://dx.doi.org/10.1111/j.1365-2125.1988.tb05281.x http://dx.doi.org/10.1016/s0049-0172%2810%2980012-5 http://dx.doi.org/10.1007/s40262-018-0635-8 http://dx.doi.org/10.21203/rs.3.rs-16392/v1 http://dx.doi.org/10.1016/j.virusres.2020.198043 http://dx.doi.org/10.2174/1381612043383791 http://dx.doi.org/10.1021/jm0601856.s001 http://dx.doi.org/10.1111/j.1365-2125.1989.tb03439.x http://dx.doi.org/10.1016/0002-9343%2883%2991265-2 http://dx.doi.org/10.1016/0306-3623%2882%2990110-0 http://dx.doi.org/10.1124/jpet.117.245639
pro:creator	https://orcid.org/0000-0001-5930-4234 Wenjie Tan https://orcid.org/0000-0003-1624-2189
is http://purl.org/spar/cito/cites of	http://dx.doi.org/10.1007/s11845-020-02291-7 http://dx.doi.org/10.1101/2020.05.01.20087999 http://dx.doi.org/10.1111/ijd.15028 http://dx.doi.org/10.1177/2324709620933438 http://dx.doi.org/10.1080/00325481.2020.1778982 http://dx.doi.org/10.2991/jegh.k.200806.002 http://dx.doi.org/10.1007/s40264-020-00933-4 http://dx.doi.org/10.1101/2020.09.15.296228 http://dx.doi.org/10.1007/s10067-020-05376-x http://dx.doi.org/10.1007/s40495-020-00218-5 http://dx.doi.org/10.1136/annrheumdis-2020-217425 http://dx.doi.org/10.1007/bf02393882 http://dx.doi.org/10.1007/s12325-020-01460-5 http://dx.doi.org/10.1007/s40262-020-00924-9 http://dx.doi.org/10.1128/aac.00741-20 http://dx.doi.org/10.3389/fcell.2020.00616 Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin? http://dx.doi.org/10.1002/med.21724 http://dx.doi.org/10.1155/2020/7527953 http://dx.doi.org/10.5144/0256-4947.2020.365 http://dx.doi.org/10.1101/2020.05.26.114033 http://dx.doi.org/10.1101/2020.09.16.299537 Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement http://dx.doi.org/10.1007/s40261-020-00933-3 http://dx.doi.org/10.1016/j.autrev.2020.102574 RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial http://dx.doi.org/10.1016/j.jaut.2020.102468 http://dx.doi.org/10.1038/s41415-020-1711-7 http://dx.doi.org/10.1038/s41421-020-0168-9 http://dx.doi.org/10.1093/jac/dkaa191 Rethinking the role of hydroxychloroquine in the treatment of COVID‐19 http://dx.doi.org/10.1101/2020.08.28.271957 http://dx.doi.org/10.1128/aac.00483-20 Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned http://dx.doi.org/10.1186/s13613-020-00661-z http://dx.doi.org/10.1208/s12249-020-01756-3 http://dx.doi.org/10.3390/cells9061461 http://dx.doi.org/10.3390/diagnostics10040243 SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses http://dx.doi.org/10.3906/sag-2004-168 National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy http://dx.doi.org/10.1007/s11427-020-1732-2 http://dx.doi.org/10.1007/s40257-020-00514-2 COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact http://dx.doi.org/10.1016/j.drudis.2020.09.010 http://dx.doi.org/10.1016/j.jaad.2020.04.017 http://dx.doi.org/10.1016/s2055-6640(20)30018-2 http://dx.doi.org/10.1038/s41419-020-2721-8 http://dx.doi.org/10.1038/s41433-020-0934-9 Treatments in the COVID-19 pandemic: an update on clinical trials http://dx.doi.org/10.1093/abt/tbaa007 http://dx.doi.org/10.1101/2020.07.17.20156059 http://dx.doi.org/10.1186/s13054-020-02932-4 http://dx.doi.org/10.3748/wjg.v26.i14.1546 http://dx.doi.org/10.1016/j.jaip.2020.04.014 http://dx.doi.org/10.1016/j.nmni.2020.100684 Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives http://dx.doi.org/10.1101/2020.04.24.20078303 http://dx.doi.org/10.1101/2020.06.26.20056507 http://dx.doi.org/10.2139/ssrn.3588532 http://dx.doi.org/10.3390/jcm9072084 http://dx.doi.org/10.3892/ijmm.2020.4608 http://dx.doi.org/10.1007/s005850050784 http://dx.doi.org/10.1007/s41403-020-00111-z http://dx.doi.org/10.3390/nano10040802 Repurposed prophylaxis strategies for COVID-19: a review http://dx.doi.org/10.1101/2020.07.09.196618 http://dx.doi.org/10.3390/jcm9061944 http://dx.doi.org/10.4155/fmc-2020-0158 http://dx.doi.org/10.3390/medicina56060315 http://dx.doi.org/10.1016/j.amjms.2020.08.019 Clinical trial protocols of repurposed prophylaxis for COVID-19: A review http://dx.doi.org/10.1093/ndt/gfaa191 http://dx.doi.org/10.1111/eci.13383 http://dx.doi.org/10.1016/j.mehy.2020.110198 http://dx.doi.org/10.1093/function/zqaa012 http://dx.doi.org/10.1016/s2665-9913(20)30305-2

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software